Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma

Clinical Pharmacokinetics

Volumn 41, Issue 13, 2002, Pages 1095-1104

  Rousseau, A ^a,b   Sabot, C ^a   Delepine, N ^c   Delepine, G ^c   Debord, J ^a   Lachatre G ^a,b   Marquet, P ^a  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF LIMOGES   (France)

^c AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

ACCURACY; ADOLESCENT; ADULT; ADULT DISEASE; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; CHILD; CHILDHOOD CANCER; COMPARTMENT MODEL; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXPOSURE; HUMAN; MAJOR CLINICAL STUDY; NONLINEAR REGRESSION ANALYSIS; NONPARAMETRIC TEST; OSTEOSARCOMA; PREDICTION; PRIORITY JOURNAL; SAMPLING;

EID: 0036035302     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200241130-00006     Document Type: Article

References (29)

1. Masson E, Relling MV, Synold TW, et al. Accumulation of methotrexatepolyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. J Clin Invest 1996; 97: 73-80
2. Goldie JH, Price LA, Harrap KR. Methotrexate toxicity: Correlation with duration of administration: Plasma levels, dose and excretion pattern. Eur J Cancer 1972; 8: 409-14
3. Stoller RG, Hande KR, Jacobs SA, et al. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 1977; 297; 630-4
4. Evans WE, Pratt C, Taylor RH, et al. Pharmacokinetic monitoring of high-dose methotrexate: Early recognition of high-risk patients. Cancer Chemother Pharmacol 1979; 3: 161-6
5. Evans WE, Relling MV, Rodman JH, et al. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998; 338: 499-505
6. Evans WE, Crom WR, Abromowitch M, et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. N Engl J Med 1986; 314: 471-7
7. Delepine N, Delepine G, Bacci G, et al. Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma: Analysis of the literature. Cancer 1996; 78: 2127-35
8. Delepine N, Delepine G, Jasmin C, et al. Importance of age and methotrexate dosage: Prognosis in children and young adults with high-grade osteosarcomas. Biomed Pharmacother 1988; 42: 257-62
9. Delepine N, Delepine G, Comille H, et al. Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma. Anticancer Res 1995; 15: 489-94
10. Graf N, Winkler K, Betlemovic M, et al. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol 1994; 12: 1443-51
11. Bacci G, Ferrari S, Delepine N, et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: Study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol 1998; 16: 658-63
12. Rosen G, Marcove RC, Caparros B, et al. Primary osteogenic sarcoma: The rationale for preoperative chemotherapy and delayed surgery. Cancer 1979; 43: 2163-77
13. Rosen G, Caparros B, Huvos A, et al. Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982; 49: 1221-30
14. Winkler K, Beton G. Koltz R, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: Results of a cooperative German/Austrian study. J Clin Oncol 1984; 2: 617-24
15. Sabot C, Debord J, Roullet B, et al. Bayesian estimation and population pharmacokinetic parameters of high dose methotrexate in osteosarcoma. Clin Res Reg Affairs 1993; 10: 233-41
16. Pignon T, Lacarelle B, Duffaud F. et al. Pharmacokinetic of high-dose methotrexate in adult osteogenic sarcoma. Cancer Chemother Pharmacol 1994; 33: 420-4
17. Sabot C, Debord J, Roullet B, et al. Comparison of 2- and 3-compartment models for the Bayesian estimation of methotrexate pharmacokinetics. Int J Clin Pharmacol Ther 1995; 33: 164-9
18. Sabot C, Marquet P, Debord J, et al. Bayesian pharmacokinetic estimation of vinorelbine in non-small-cell lung cancer patients. Eur J Pharmacol 1998; 54: 171-5
19. D'Argenio DZ, Schumitzky A. ADAPT II User's Guide. University of Southern California, Los Angeles (CA): Biomedical Simulations Resource, 1990
20. Delepine N, Desbois JC, Delepine G, et al. Individualization of the dosage of high-dose methotrexate by assaying plasma concentration: Therapeutic value in osteogenic sarcoma. Bull Cancer 1989; 76: 913-8
21. Raude E, Oellerich M, Weinel P, et al. High dose methotrexate: Pharmacokinetics in children and young adults. Int J Clin Pharmacol Ther 1988; 26: 364-70
22. Jelliffe RW, Schumitzky A, Bayard D, et al. Model-based, goal oriented individualized drug therapy. Clin Pharmacokinet 1998; 34: 57-77
23. Jelliffe R, Bayard D, Milman M, et al. Achieving target goals most precisely using nonparametric compartmental models and 'multiple model' design of dosage regimens. Ther Drug Monit 2000; 22: 346-53
24. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503-12
25. Bellissant E, Sébille V, Paintaud G. Methodological issues in pharmacokinetic-pharmacodynamic modelling. Clin Pharmacokinet 1998; 35: 151-66
26. Rousseau A, Marquet P, Debord J. Adaptive control methods for the dose individualisation of anticancer agents. Clin Pharmacokinet 2000; 38: 315-63
27. Odoul F, Le Guellec C, Lamagnère JP, et al. Prediction of methotrexate elimination after high-dose infusion in children with acute lymphoblastic leukemia using a population pharmacokinetic approach. Fundam Clin Pharmacol 1999; 13: 595-604
28. Borsi JD, Moe PJ. Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children. Cancer 1987; 60: 3020-4
29. Donelli MG, Zucchetti M, Robatto A, et al. Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia. Med Pediatr Oncol 1995; 24: 154-9